Table 1.
Baseline and demographic data.
| Variable | Overall Cohort (n = 649) |
Centre A (n = 335) |
Centre B (n = 88) |
Centre C (n = 226) |
p |
|---|---|---|---|---|---|
| Age (yrs, median, IQR) | 64 (55–72) | 64 (55–72) | 63 (54.2–71) | 62.5 (54–72.5) | 0.710 |
| Gender (n,%) Male Female |
416 (64%) 233 (36%) |
216 (64.5%) 119 (35.5%) |
52 (59.1%) 36 (40.9%) |
148 (65.5%) 78 (34.5%) |
0.557 |
| ASA score (n,%) 1–2 3–4 |
514 (79.1%) 135 (20.9%) |
251 (74.9%) 84 (25.1%) |
72 (81.8%) 16 (18.2%) |
191 (84.5%) 35 (15.5%) |
0.01 |
| Diabetes (n,%) | 60 (9.2%) | 32 (9.5%) | 14 (15.9%) | 14 (6.2%) | 0.02 |
| Hypertension (n,%) | 197 (30.3%) | 122 (36.4%) | 46 (52.2%) | 29 (12.8%) | 0.001 |
| Surgical approach (n,%) Open Laparoscopic Robotic |
109 (16.7%) 59 (9.2%) 481 (74.1%) |
109 (32.5%) 57 (17%) 169 (50.4%) |
- 2 (2.3%) 86 (97.7%) |
- - 226 (100%) |
0.001 |
| Clinical tumor size (cm, median, IQR) | 3.3 (2.4–4.5) | 3.2 (2.2–4.2) | 3.9(2.6–5) | 3.2 (2.5–4.5) | 0.06 |
| RENAL score (n,%) 4–6 7–9 10–12 |
282 (43.4%) 241 (37.1%) 126 (19.5%) |
143 (42.6%) 120 (35.8%) 72 (21.7%) |
31 (34%) 42 (47.7%) 15 (17%) |
108 (47.8%) 79 (35%) 39 (17.2%) |
0.124 |
| Preoperative eGFR (mL/min/1.73 m2, median, IQR) | 83 (69–98.6) | 82.2 (69.3–95.3) | 90.2 (67–118) | 81.5 (70–97.7) | 0.001 |
| Preoperative cT stage (n,%) 1a 1b 2a 2b |
440 (67.8%) 168 (25.9%) 35 (5.4%) 6 (0.9%) |
248 (74%) 73 (21.7%) 14 (4.1%) - |
49 (55.6%) 31 (35.2%) 4 (4.5%) 4 (4.5%) |
143 (63.2%) 64 (28.3%) 17 (7.5%) 2 (1%) |
0.001 |
| Preoperative CKD stage (n,%) 1 2 3a 3b 4 5 |
232 (35.8%) 317 (48.6%) 68 (10.5%) 20 (3.1%) 10 (1.6%) 2 (0.4%) |
120 (35.8%) 165 (49.2%) 34 (10.1%) 8 (2.38%) 8 (2.38%) - |
45 (51.1%) 34 (38.6%) 7 (7.9%) 2 (2.2%) - |
67 (29.7%) 118 (52.3%) 27 (12%) 10 (4.4%) 2 (0.8%) 2 (0.8%) |
0.09 |